Cystic Fibrosis Foundation: Achieving the Mission

Marshall, Bruce C.; Penland, Chris M.; Hazle, Leslie; Ashlock, Melissa; Wetmore, Diana; Campbell III, Preston W.; Beall, and Robert J.
June 2009
Respiratory Care;Jun2009, Vol. 54 Issue 6, p788
Academic Journal
The Cystic Fibrosis Foundation is a voluntary, nonprofit, health organization whose mission is "to assure the development of the means to cure and control cystic fibrosis and to improve the quality of life for those with the disease." While substantial progress has been made, as evidenced by a marked increase in the median predicted age of survival, much work remains to be done. Ongoing medical programs and activities of the Cystic Fibrosis Foundation, which span basic science, drug discovery, drug development, clinical care, patient education, and advocacy, will be described in this article. The key role of respiratory therapists in the cystic fibrosis community will be highlighted.


Related Articles

  • Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Clancy, J. P.; Dupont, L.; Konstan, M. W.; Billings, J.; Fustik, S.; Goss, C. H.; Lymp, J.; Minic, P.; Quittner, A. L.; Rubenstein, R. C.; Young, K. R.; Saiman, L.; Burns, J. L.; Govan, J. R. W.; Ramsey, B.; Gupta, R. // Thorax;Sep2013, Vol. 68 Issue 9, p818 

    Rationale: Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. Objectives: To examine the safety and efficacy of 28 days of once-daily Arikace in cystic fibrosis (CF) patients chronically infected with P...

  • New therapy marks a milestone in fight against cystic fibrosis.  // Biomedical Market Newsletter;11/9/2011, Vol. 21, p610 

    The article reports on a study which examines the impact of the drug ivacaftor on patients with cystic fibrosis (CF). Findings reveal that the said drug can significantly improve the lung function of CF-affected persons. It notes that the discovery can open new opportunities for the treatment of CF.

  • Disparities in health outcomes for CF unexplained.  // PharmacoEconomics & Outcomes News;1/23/2010, Issue 595, p8 

    The article discusses research on the association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis, that references a study by M. S. Schechter and colleagues published in the November 2009 issue of the "Journal of Pediatrics."

  • Cystic fibrosis -- economic analysis of the TIGER-1 study.  // PharmacoEconomics & Outcomes News;4/28/2012, Issue 652, p6 

    The article discusses research on the resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function, referencing a study by E. M. Dewitt and colleagues published in the March 2012 issue of "Value in Health."

  • Cost of cystic fibrosis increases with worsening severity.  // PharmacoEconomics & Outcomes News;9/1/2012, Issue 661, p5 

    The article discusses research on the treatment costs of cystic fibrosis (CF) in relation to its severity, referencing a study by M. Heimeshoff and colleagues published in a 2012 issue of "PharmacoEconomics."

  • New treatments in adult cystic fibrosis. Bilton, Diana; Mahadeva, Ravi // Journal of the Royal Society of Medicine (Supplement);Feb1997, Vol. 90 Issue 31, p2 

    The article reports on the development of new treatments in adult cystic fibrosis. One study in which usual antibiotic therapy was discontinued showed a reduction in decline of lung function in the amiloride treated group compared to placebo. Another study in Great Britain in which optimal...

  • More Positive Data for CF Drug; Vertex Eyes 2H11 NDA.  // Bioworld Week;4/4/2011, Vol. 19 Issue 14, p3 

    The article reports on a positive data for cystic fibrosis (CF) drug VX-770 in adult patients as well as the revelation of a study by Vertex Pharmaceuticals Inc. which involves 6 to 11 aged children that shows a good trend towards support on the proposed new drug application (NDA).

  • Vertex CF Results Positive, But No Home Run.  // Bioworld Week;6/13/2011, Vol. 19 Issue 24, p5 

    The article reports that the phase two trial conducted by Vertex Pharmaceuticals Inc. involving the combination of two drugs for cystic fibrosis (CF) had shown positive interim results but these are not viewed as home run.

  • Self-care in the classroom for children with chronic illness: A case study of a student with... Cox, Julie Elizabeth // Elementary School Guidance & Counseling;Dec94, Vol. 29 Issue 2, p121 

    Focuses on a classroom self-care case study of a student with cystic fibrosis. Cystic fibrosis as a genetically transmitted condition in children that causes significant morbidity and early mortality; Significance of Section 504 of the Rehabilitation Act of 1973 on discrimination against...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics